{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:33:58Z","timestamp":1785227638915,"version":"3.55.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jaci.2022.12.809","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T11:15:02Z","timestamp":1672312502000},"page":"1005-1014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Unveiling chronic spontaneous urticaria pathophysiology through systems biology"],"prefix":"10.1016","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8215-872X","authenticated-orcid":false,"given":"Cristina","family":"Seg\u00fa-Verg\u00e9s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6855-9917","authenticated-orcid":false,"given":"Jessica","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0054-9293","authenticated-orcid":false,"given":"Pau","family":"Terradas-Montana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4253-6682","authenticated-orcid":false,"given":"Laura","family":"Artigas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Smeets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8495-1302","authenticated-orcid":false,"given":"Marta","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7910-0554","authenticated-orcid":false,"given":"Sinisa","family":"Savic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2022.12.809_bib1","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2022.12.809_bib2","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1111\/all.13878","article-title":"Diagnosis and treatment of chronic inducible urticaria","volume":"74","author":"Maurer","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2022.12.809_bib3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/ACI.0000000000000466","article-title":"New biologics in the treatment of urticaria","volume":"18","author":"Kocat\u00fcrk","year":"2018","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.12.809_bib4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000507218","article-title":"Urticaria: Collegium Internationale Allergologicum (CIA) update 2020","volume":"181","author":"Maurer","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2022.12.809_bib5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","article-title":"Unmet clinical needs in chronic spontaneous urticaria. A\u00a0GA2LEN task force report","volume":"66","author":"Maurer","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2022.12.809_bib6","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2015.12.1342","article-title":"Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials","volume":"137","author":"Zhao","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.12.809_bib7","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2017.01.042","article-title":"Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial","volume":"140","author":"Maurer","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.12.809_bib8","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4168\/aair.2017.9.6.477","article-title":"Chronic spontaneous urticaria: pathogenesis and treatment considerations","volume":"9","author":"Kaplan","year":"2017","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaci.2022.12.809_bib9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.iac.2013.09.011","article-title":"Urticaria: impact on quality of life and economic cost","volume":"34","author":"O'Donnell","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2022.12.809_bib10","first-page":"214","article-title":"Epidemiology of urticaria in Spain","volume":"14","author":"Gaig","year":"2004","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaci.2022.12.809_bib11","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/bjd.14470","article-title":"Epidemiology of chronic spontaneous urticaria: results from a nationwide, population-based study in Italy","volume":"174","author":"Lapi","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2022.12.809_bib12","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2230.2010.03840.x","article-title":"Epidemiology of urticaria: a representative cross-sectional population survey","volume":"35","author":"Zuberbier","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2022.12.809_bib13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13601-015-0074-7","article-title":"Immunological events in chronic spontaneous urticaria","volume":"5","author":"Ferrer","year":"2015","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaci.2022.12.809_bib14","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaip.2018.04.013","article-title":"Chronic spontaneous urticaria: the devil's itch","volume":"6","author":"Saini","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.12.809_bib15","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2222.2005.02212.x","article-title":"Increased responsiveness of basophils of patients with chronic urticaria to sera but hypo-responsiveness to other stimuli","volume":"35","author":"Luquin","year":"2005","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2022.12.809_bib16","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/1523-1747.ep12338544","article-title":"Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria","volume":"106","author":"Niimi","year":"1996","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2022.12.809_bib17","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1067\/mai.2002.123236","article-title":"TH1\/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction","volume":"109","author":"Ying","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.12.809_bib18","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3389\/fimmu.2019.00627","article-title":"Autoimmune theories of chronic spontaneous urticaria","volume":"10","author":"Bracken","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2022.12.809_bib19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.anai.2019.08.014","article-title":"New treatments for chronic urticaria","volume":"124","author":"Kolkhir","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2022.12.809_bib20","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.jaip.2021.03.033","article-title":"The pathogenesis of chronic spontaneous urticaria: the role of infiltrating cells","volume":"9","author":"Gim\u00e9nez-Arnau","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.12.809_bib21","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0091-6749(98)70176-9","article-title":"Comparative studies of functional and binding assays for IgG anti-Fc(epsilon)RIalpha (alpha-subunit) in chronic urticaria","volume":"101","author":"Ferrer","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.12.809_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/all.12056","article-title":"EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria","volume":"68","author":"Konstantinou","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2022.12.809_bib23","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1111\/jdv.15640","article-title":"Immunological effects and potential mechanisms of action of autologous serum therapy in chronic spontaneous urticaria","volume":"33","author":"Yu","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2022.12.809_bib24","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/all.13949","article-title":"Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study","volume":"74","author":"Schoepke","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2022.12.809_bib25","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.jaci.2021.12.772","article-title":"An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria","volume":"149","author":"Altrichter","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.12.809_bib26","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.12.809_bib27","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaci.2015.08.023","article-title":"Timing and duration of omalizumab response in patients with chronic idiopathic\/spontaneous urticaria","volume":"137","author":"Kaplan","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.12.809_bib28","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1684\/ejd.2017.3085","article-title":"Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria","volume":"27","author":"Ferrer","year":"2017","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaci.2022.12.809_bib29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.23822\/EurAnnACI.1764-1489.167","article-title":"Omalizumab in severe chronic urticaria: are slow and non-responders different?","volume":"53","author":"Asero","year":"2021","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.12.809_bib30","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaci.2016.07.047","article-title":"Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria","volume":"139","author":"Gericke","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.12.809_bib31","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jaip.2015.04.015","article-title":"Similar efficacy with omalizumab in chronic idiopathic\/spontaneous urticaria despite different background therapy","volume":"3","author":"Casale","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.12.809_bib32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamadermatol.2018.3447","article-title":"Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of \"real-world\" evidence","volume":"155","author":"Tharp","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2022.12.809_bib33","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/ecco-jcc\/jjy171","article-title":"ANP32E, a protein involved in steroid-refractoriness in ulcerative colitis, identified by a systems biology approach","volume":"13","author":"Lor\u00e9n","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jaci.2022.12.809_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240149","article-title":"In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm","volume":"15","author":"Artigas","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2022.12.809_bib35","doi-asserted-by":"crossref","first-page":"316","DOI":"10.18632\/oncotarget.27875","article-title":"Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach","volume":"12","author":"Carcereny","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaci.2022.12.809_bib36","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.neubiorev.2017.08.019","article-title":"Treatment resistant depression: a multi-scale, systems biology approach","volume":"84","author":"Akil","year":"2018","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.jaci.2022.12.809_bib37","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13075-021-02507-w","article-title":"Application of systems biology-based in silico tools to optimize treatment strategy identification in Still's disease","volume":"23","author":"Seg\u00fa-Verg\u00e9s","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2022.12.809_bib38","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.copbio.2019.03.005","article-title":"Dynamical systems approaches to personalized medicine","volume":"58","author":"Davis","year":"2019","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.jaci.2022.12.809_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228926","article-title":"In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan","volume":"15","author":"Jorba","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2022.12.809_bib40","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jacbts.2019.07.010","article-title":"Unraveling the molecular mechanism of action of empagliflozin in heart failure with reduced ejection fraction with or without diabetes","volume":"4","author":"Iborra-Egea","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jaci.2022.12.809_bib41","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fendo.2020.00258","article-title":"Repurposed analog of GLP-1 ameliorates hyperglycemia in type 1 diabetic mice through pancreatic cell reprogramming","volume":"11","author":"Villalba","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jaci.2022.12.809_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147626","article-title":"Novel neuroprotective multicomponent therapy for amyotrophic lateral sclerosis designed by networked systems","volume":"11","author":"Herrando-Grabulosa","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2022.12.809_bib43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/nar\/30.1.207","article-title":"Gene Expression Omnibus: NCBI gene expression and hybridization array data repository","volume":"30","author":"Edgar","year":"2002","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jaci.2022.12.809_bib44","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/all.13183","article-title":"Transcriptome analysis of severely active chronic spontaneous urticaria shows an overall immunological skin involvement","volume":"72","author":"Gim\u00e9nez-Arnau","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2022.12.809_bib45","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2500\/ar.2015.6.0124","article-title":"Gene expression profiles in chronic idiopathic (spontaneous) urticaria","volume":"6","author":"Patel","year":"2015","journal-title":"Allergy Rhinol (Providence)"},{"issue":"Database issue","key":"10.1016\/j.jaci.2022.12.809_bib46","doi-asserted-by":"crossref","first-page":"D1005","DOI":"10.1093\/nar\/gkq1184","article-title":"NCBI GEO: archive for functional genomics data sets--10 years on","volume":"39","author":"Barrett","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jaci.2022.12.809_bib47","doi-asserted-by":"crossref","first-page":"D668","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: a comprehensive resource for in silico drug discovery and exploration","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jaci.2022.12.809_bib48","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jaci.2022.12.809_bib49","doi-asserted-by":"crossref","first-page":"D380","DOI":"10.1093\/nar\/gkv1277","article-title":"STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data","volume":"44","author":"Szklarczyk","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jaci.2022.12.809_bib50","doi-asserted-by":"crossref","first-page":"D919","DOI":"10.1093\/nar\/gkm862","article-title":"SuperTarget and Matador: resources for exploring drug-target relationships","volume":"36","author":"G\u00fcnther","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jaci.2022.12.809_bib51","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res"},{"key":"10.1016\/j.jaci.2022.12.809_bib52","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/eji.200535464","article-title":"Histamine modulates mast cell degranulation through an indirect mechanism in a model IgE-mediated reaction","volume":"36","author":"Carlos","year":"2006","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaci.2022.12.809_bib53","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/bjd.14768","article-title":"Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis","volume":"175","author":"Guill\u00e9n-Aguinaga","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2022.12.809_bib54","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/cea.12668","article-title":"Comparable actions of omalizumab on mast cells and basophils","volume":"46","author":"Serrano-Candelas","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2022.12.809_bib55","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1111\/all.13586","article-title":"Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab","volume":"73","author":"Weller","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2022.12.809_bib56","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4168\/aair.2021.13.2.206","article-title":"Total IgE as a marker for chronic spontaneous urticaria","volume":"13","author":"Altrichter","year":"2021","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaci.2022.12.809_bib57","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jaci.2016.08.050","article-title":"Autoimmune chronic spontaneous urticaria: what we know and what we do not know","volume":"139","author":"Kolkhir","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.12.809_bib58","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jaip.2019.01.026","article-title":"Relevance of the basophil high-affinity ige receptor in chronic urticaria: clinical experience from a tertiary care institution","volume":"7","author":"Deza","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.12.809_bib59","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/j.1365-2133.2008.08499.x","article-title":"Activated status of basophils in chronic urticaria leads to interleukin-3 hyper-responsiveness and enhancement of histamine release induced by anti-IgE stimulus","volume":"158","author":"Louren\u00e7o","year":"2008","journal-title":"Br J Dermatol"},{"issue":"4 Pt 1","key":"10.1016\/j.jaci.2022.12.809_bib60","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0091-6749(98)70283-0","article-title":"Anti-Fc(episilon)RI auto antibodies and basophil histamine releasability in chronic idiopathic urticaria","volume":"102","author":"Sabroe","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.12.809_bib61","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/all.12578","article-title":"Interval shifts in basophil measures correlate with disease activity in chronic spontaneous urticaria","volume":"70","author":"Oliver","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2022.12.809_bib62","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.anai.2019.08.465","article-title":"Current and emerging treatments for chronic spontaneous urticaria","volume":"125","author":"Johal","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2022.12.809_bib63","series-title":"Urticaria \u2013 diagnosis and management","article-title":"New Biological Treatment Options in CSU","author":"Vadasz","year":"2021"},{"key":"10.1016\/j.jaci.2022.12.809_bib64","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1111\/bcp.14923","article-title":"Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: results of a phase 1a\/b randomised double-blind placebo-controlled study","volume":"87","author":"Dickson","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaci.2022.12.809_bib65","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/all.14713","article-title":"Treatment of chronic spontaneous urticaria with benralizumab: report of primary endpoint per-protocol analysis and exploratory endpoints","volume":"76","author":"Bernstein","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2022.12.809_bib66","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1056\/NEJMc2016395","article-title":"Benralizumab for chronic spontaneous urticaria","volume":"383","author":"Bernstein","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.12.809_bib67","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41591-021-01537-w","article-title":"Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial","volume":"27","author":"Metz","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2022.12.809_bib68","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1111\/cts.13005","article-title":"Remibrutinib (LOU064): a selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial","volume":"14","author":"Kaul","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jaci.2022.12.809_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.741170","article-title":"Methods to develop an in silico clinical trial: computational head-to-head comparison of lisdexamfetamine and methylphenidate","volume":"12","author":"Guti\u00e9rrez-Casares","year":"2021","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.jaci.2022.12.809_bib70","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ad.2016.07.018","article-title":"Omalizumab in the treatment of chronic inducible urticaria","volume":"108","author":"Chicharro","year":"2017","journal-title":"Actas Dermosifiliogr"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674922025763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674922025763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:40:57Z","timestamp":1758793257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674922025763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0091674922025763"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2022.12.809","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unveiling chronic spontaneous urticaria pathophysiology through systems biology","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2022.12.809","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}